This study explores trends and potential risk factors among pediatric patients with drug-resistant epilepsy who were prescribed cenobamate by their epileptologist. Twenty-four patients (54.2% female) with drug-resistant (62.5% focal) epilepsy were administered cenobamate (mean = 13.27 years, standard deviation [SD] = 4.91 years) after failing multiple antiseizure medications (mean = 4.83, SD = 2.94). Fifty percent reported improved seizure frequency, although more than half the sample experienced physiological (n = 12, 50%) and/or psychiatric (n = 4, 16.7%) adverse events, with 39% rapidly discontinuing cenobamate (mean = 4.00 months, SD = 3.21) because of intolerable physiological (n = 4, 57.1%) and/or psychiatric adverse events (n = 3, 42.9%). Of those experiencing a psychiatric adverse event, all but 1 (75%) discontinued cenobamate, as compared to discontinuation by only 40% of those experiencing a physiological adverse event (n = 10). Psychiatric adverse events were significantly associated with sex (100% female), χ2(1, N = 24) = 4.06, P = .04. Preliminary analyses also suggest older age (adolescence) may increase risk for psychiatric adverse events of cenobamate among patients with pediatric epilepsy.
OhAThurmanDJKimH. Comorbidities and risk factors associated with newly diagnosed epilepsy in the US pediatric population. Epilepsy Behav.2017;75:230–236. doi:https://doi.org/10.1016/j.yebeh.2017.07.040
2.
RussSALarsonKHalfonN. A national profile of childhood epilepsy and seizure disorder. Pediatrics. 2012;129(2):256–264. doi:https://doi.org/10.1542/peds.2010-1371
3.
ReillyCAtkinsonPDasKB, et al.Factors associated with quality of life in active childhood epilepsy: a population-based study. Eur J Paediatr Neurol.2015;19(3):308–313. doi:https://doi.org/10.1016/j.ejpn.2014.12.022
KwanPArzimanoglouABergAT, et al.Definition of drug-resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–1077. doi:https://doi.org/10.1111/j.1528-1167.2009.02397.x
6.
MakridisKLBastTPragerC, et al.Real-world experience treating pediatric epilepsy patients with cenobamate. Front Neurol.2022;13:950171. doi:https://doi.org/10.3389/fneur.2022.950171
7.
KalilaniLSunXPelgrimsBNoack-RinkMVillanuevaV. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59(12):2179–2193. https://doi.org/10.1111/epi.14596
8.
KleinPAboumatarSBrandtC, et al.Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989–e998.
9.
ChungSSFrenchJAKowalskiJ,et al.Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311–e2322. doi:https://doi.org/10.1212/WNL.0000000000009530
10.
KraussGLKleinPBrandtC,et al.Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind randomised, placebo-controlled, dose-response trial. Lancet Neurol.2020;19(1):38–48. doi:https://doi.org/10.1016/S1474-4422(19)30399-0
11.
SperlingMRKleinPAboumatarS,et al.Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099–1108. doi:https://doi.org/10.1111/epi.16525
12.
KraussGLChungSSFerrariLSternSRosenfeldWE. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy Behav.2024;151:109605. doi:https://doi.org/10.1016/j.yebeh.2023.109605
13.
ElliottTRidley-PryorTGienappAJWhelessJW. Initial real-world experience with cenobamate in adolescents and adults: a single center experience. Pediatr Neurol.2022;129:19–23. doi:https://doi.org/10.1016/j.pediatrneurol.2022.01.001
14.
VarugheseRTShahYDKarkareSKothareSV. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study. Epilepsy Behav.2022;130:108679. doi:https://doi.org/10.1016/j.yebeh.2022.108679
15.
EddyCMRickardsHECavannaAE. Behavioral adverse effects of antiepileptic drugs in epilepsy. J Clin Psychopharmacol.2012;32(3):362–375. doi:https://doi.org/10.1097/JCP.0b013e318253a186
16.
MichaelisRTangVGoldsteinLH,et al.Psychological treatments for adults and children with epilepsy: evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. Epilepsia. 2018;59(7):1282–1302. doi:https://doi.org/10.1111/epi.14444
17.
ClaryLEVander WalJSTitusJB. Examining health-related quality of life, adaptive skills, and psychological functioning in children and adolescents with epilepsy presenting for a neuropsychological evaluation. Epilepsy Behav.2010;19(3):487–493. doi:https://doi.org/10.1016/j.yebeh.2010.08.002
Hernández GarcíaENaranjoLPichardo-MacíasLA, et al.Analysis of adverse drug reactions in pediatric patients with epilepsy: an intensive pharmacovigilance study. Children (Basel, Switzerland). 2023;10(11):1775. https://doi.org/10.3390/children10111775
20.
HesdorfferDCIshiharaLMynepalliLWebbDJWeilJHauserWA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol.2012;72(2):184–191. https://doi.org/10.1002/ana.23601
SazgarMMnatsakanyanLPackAMHardenCL. Epilepsy and anti-seizure medications: secret agents for endocrine disruption. Epilepsy Curr. 2024;24(2):79–83. https://doi.org/10.1177/15357597231213248
24.
ConnorGSWilliamsonA. Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice. Epilepsy Behav Rep. 2022;18:100533. https://doi.org/10.1016/j.ebr.2022.100533
